42 results
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
3:28pm
pandemic, and actions taken by governmental authorities or others in connection therewith;
our need to complete extensive clinical trials and the risk
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
19 Apr 24
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
9:21am
pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith, and such other risks which
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
9:17am
the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith;
our need to complete extensive clinical
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
18 Apr 24
Other Events
9:13am
pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith, and such other risks which
8-K
EX-99.1
i26eoej
15 Apr 24
Bio-Path Holdings Expands Global Patent Portfolio
7:30am
424B5
qa4eda8
4 Apr 24
Prospectus supplement for primary offering
4:33pm
8-K
EX-99.1
qn4j70hw 0bmq
2 Apr 24
Bio-Path Holdings Provides 2024 Clinical and Operational Update
4:10pm
424B5
cftzl5aym68xog rk
27 Mar 24
Prospectus supplement for primary offering
8:15am
8-K
EX-99.1
16nj9
8 Mar 24
Bio-path Holdings Reports Full Year 2023 Financial Results
7:10am
8-K
EX-99.1
u9rmap ero1n
23 Feb 24
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
7:01am
8-K
EX-99.1
y02mp
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
8-K
EX-99.1
7fr fnsvklczdvk
14 Dec 23
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
4:05pm
8-K
EX-99.1
v1uk26zukvrci
15 Nov 23
Bio-path Holdings Reports Third Quarter 2023 Financial Results
7:30am